| Literature DB >> 23622561 |
Osvaldo Marinotti1, Nijole Jasinskiene, Aniko Fazekas, Sarah Scaife, Guoliang Fu, Stefanie T Mattingly, Karissa Chow, David M Brown, Luke Alphey, Anthony A James.
Abstract
BACKGROUND: Transgenic mosquito strains are being developed to contribute to the control of dengue and malaria transmission. One approach uses genetic manipulation to confer conditional, female-specific dominant lethality phenotypes. Engineering of a female-specific flightless phenotype provides a sexing mechanism essential for male-only mosquito, release approaches that result in population suppression of target vector species.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23622561 PMCID: PMC3648444 DOI: 10.1186/1475-2875-12-142
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Figure 1Schematic representations of the transformation constructs OX3545, AsOX3545 and OX3547, and the mechanism of action of the double transgene-based female-specific RIDL. OX3545 and OX3547 were previously described in detail [2]. AsOX3545 is a similar to OX3545, with the Anopheles stephensi Actin-4 regulatory sequences replacing the Aedes aegypti Actin-4 sequence. Actin 4 promoters (Act4P) drive the expression of the tetracycline-repressible transactivator protein (tTa) in the flight muscles of adult female mosquitoes. tTA binds tetO in the absence of tetracycline, driving expression of the effector molecule, Nuclear Inhibitor of PP1 (Nipp1Dm) [22,23], leading to disruption of normal cell functions. Tetracycline prevents tTa binding to tetO abolishing expression of Nipp1Dm. The positions of the SpeI recognition and cleavage sites in OX3545, AsOX3545 and OX3547 are indicated by vertically oriented arrows. Horizontally oriented arrows indicate the direction of transcription for each component of the constructs. Abbreviations: pBac R and L, piggyBac right and left inverted repeats, respectively; attB, φC31 recombination site; DsRed2, red fluorescent protein open reading frame; IE1, baculovirus immediate-early gene promoter driving DsRed2 expressed throughout the body; 3×P3, artificial promoter consisting of a multimer of the binding site (P3), driving high levels of expression in the eye.
Sex ratio and survival of driver transgenic lines carrying the promoter (OX3545 construct)
| DAa-1 ♂ | 1 ♂ | 325 | 199 | 0 | 17 |
| DAa-2 ♂ | 4 ♂ | 680 | 138 | 21 | 22 |
| DAa-3 ♂ | 1 ♂ | 200 | 86 | 3 | 29 |
| DAa-4 ♂ | 17 ♂ | 1140 | 659 | 31 | 134 |
| DAa-5 ♂ | 4 ♂ | 90 | 45 | 3 | 11 |
| DAa-6 ♀ | 1 ♂ | 70 | 44 | 22 | 9 |
| DAa-7 ♀ | 1 ♂ | 100 | 45 | 9 | 15 |
| DAa-8 ♀ | 1 ♂ | 90 | 30 | 10 | 17 |
| DAa-9 ♂ | 1 ♂, 2 ♀ | 0 | 0 | 0 | 0 |
| DAa-10 ♂ | 1 ♂ | 0 | 0 | 0 | 0 |
| DAa-11 ♂ | 2 ♂ | 0 | 0 | 0 | 0 |
| DAa-12 ♂ | 1 ♂ | 0 | 0 | 0 | 0 |
| DAa-13 ♂ | 2 ♂ | 0 | 0 | 0 | 0 |
| DAa-14 ♂ | 1 ♂ | 0 | 0 | 0 | 0 |
| DAa-15 ♂ | 1 ♀ | 0 | 0 | 0 | 0 |
*A flightless phenotype was not observed in males or females. An expanded Table showing results of five generations is provided as Additional file 2: Table S1.
Figure 2Southern blot detection of transgenes integrated into the genomes of driver and effector transgenic lines. Genomic DNA extracted from a pool of mosquitoes from each line was digested with SpeI, fractionated by agarose gel electrophoresis, transferred to a Zeta-probe GT membrane and hybridized to a 32P-labelled DsRed2 open-reading frame probe. DAa, DAs and E and the numbers on top of the figures indicate the individual transgenic lines originated from injection of the OX3545 and AsOX3534 driver and OX3547 effector constructs, respectively.
Sex ratio, survival, and flightless phenotype of driver transgenic lines carrying the promoter (AsOX3545 construct)
| DAs-16 | 1 ♂ | 120 | 119 | 33/0* | 33 |
| DAs-17 | 17 ♂ | 300 | 101 | 4/21 | 36 |
| DAs-18 | 33 ♂ | 300 | 131 | 2/19 | 51 |
| DAs-19 | 1 ♂ | 210 | 129 | 0/53 | 48 |
| DAs-20 | 2 ♂ | 320 | 321 | 0/21 | 65 |
| DAs-21 | 4 ♂ | 510 | 202 | 0/37 | 95 |
| DAs-22 | 1 ♂ | 260 | 176 | 0/21 | 48 |
| DAs-23 | 1 ♂ | 170 | 147 | 0/19 | 52 |
| DAs-24 | 1 ♂ | 410 | 344 | 0/19 | 32 |
| DAs-25 | 14 ♂ | 350 | 168 | 0/19 | 35 |
| DAs-26 | 27 ♂ | 400 | 107 | 0/29 | 39 |
| DAs-27 | 4 ♂ | 70 | 62 | 0/4 | 20 |
| DAs-28 | 1 ♂ | 130 | 163 | 0/3 | 35 |
| DAs-29 | 10 ♂ | 410 | 178 | 0/8 | 17 |
| DAs-30 | 1 ♂ | 120 | 144 | 0/9 | 6 |
| DAs-31 | 1 ♀ | 300 | 46 | 0/3 | 3 |
| DAs-32 | 1 ♀ | 500 | 32 | 0/4 | 14 |
| DAs-33 | 1 ♀ | 450 | 37 | 0/4 | 3 |
| DAs-34 | 2 ♂ | 90 | 54 | 0/0 | 3 |
| DAs-35 | 1 ♀ | 400 | 47 | 0/0 | 6 |
| DAs-36 | 3 ♂ | 40 | 13 | 0/0 | 1 |
*The flightless female phenotype of line DAs-16 is not rescued by tetracycline.
Sex-ratio and survival of effector transgenic lines carrying the OX3547 construct
| E-1 (♂) | 0 ♂, 28 ♀ | G1 ♀ x WT* ♂ | 57 | 29 | 26 |
| E-2 (♂) | 0 ♂, 42 ♀ | G1 ♀ x WT ♂ | 128 | 59 | 62 |
| E-3 (♀) | 6 ♂, 2 ♀ | G1 ♂ x WT ♀ | 81 | 76 | 0 |
| E-4 (♀) | 25 ♂, 26 ♀ | G1 ♂ x WT ♀ | 32 | 27 | 0 |
*WT, wild-type.
Sex-ratio, survival, and flightless phenotypes in the F1 progeny of crosses between the effector line E-1 and driver lines engineered with either OX3545 (DAa-) or AsOX3545 (DAs-)
| DAa-1 | 775 | 144 | 0 | 1 | 62 | 63 (44%) |
| DAa-2 | 1150 | 307 | 7 | 0 | 34 | 41 (13%) |
| DAa-3 | 4340 | 880 | 9 | 172 | 345 | 517 (70%) |
| DAa-4 | 600 | 110 | 3 | 23 | 29 | 54 (49%) |
| DAa-5 | 900 | 226 | 47 | 0 | 96 | 143 (63%) |
| DAa-6 | 1830 | 371 | 140 | 0 | 143 | 283 (76%) |
| DAa-7 | 1200 | 239 | 41 | 6 | 74 | 121 (51%) |
| DAs-17 | nd | 465 | 80 | 79 | 177 | 336 (72%) |
| DAs-18 | nd | 89 | 11 | 3 | 23 | 37 (41%) |
| DAs-19 | nd | 185 | 58 | 20 | 62 | 140 (75%) |
| DAs-20 | nd | 152 | 11 | 0 | 52 | 63 (41%) |
| DAs-21* | nd | 1545 | 0 | 161 | 483 | 644 (42%) |
| DAs-22 | nd | 1483 | 3 | 397 | 507 (1)** | 907 (61%) |
| DAs-24 | nd | 93 | 23 | 4 | 28 | 55 (59%) |
| DAs-25* | nd | 761 | 0 | 70 | 193 | 263 (35%) |
| DAs-26 | nd | 328 | 15 | 86 | 112 | 213 (65%) |
| DAs-28 | nd | 244 | 19 | 0 | 73 | 92 (37%) |
| DAs-29 | nd | 107 | 33 | 0 | 33 | 66 (61%) |
| DAs-30 | nd | 226 | 15 | 0 | 14 | 29 (12%) |
| DAs-34 | nd | 114 | 8 | 0 | 0 | 8 (0%) |
| DAs-36 | nd | 267 | 21 | 0 | 46 | 67 (25%) |
*Lines with design-feature phenotypes.
**Crossing Das-22 and E-1 lines generated one flightless male (indicated in parenthesis).
Effects of tetracycline on survival and flightless phenotype of transgenic carrying driver and effector transgenes
| DAa-3 | 10 μg/ml | 2535 | 371 | 108 | 16 | 226 | 350 (94%) |
| DAa-3 | 5 μg/ml | 930 | 269 | 37 | 3 | 91 | 131 (49%) |
| DAa-3 | 1 μg/ml | 610 | 143 | 21 | 10 | 69 | 100 (70%) |
| DAa-3 | 100 ng/ml | 750 | 162 | 15 | 16 | 61 | 92 (57%) |
| DAa-3 | 10 ng/ml | 600 | 127 | 9 | 28 | 38 | 75 (59%) |
| DAs-21 | 10 μg/ml | nd | 233 | 25 | 18 | 82 | 125 (54%) |
| DAs-22 | 10 μg/ml | nd | 628 | 155 | 12 | 285 (1)* | 453 (72%) |
*One flightless male was observed among the progeny of driver DAs-22 ♂ x effector E-1 ♀ cross (indicated in parenthesis).